New drug aticaprant tested as Add-On for schizophrenia
NCT ID NCT07615426
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests whether the experimental drug aticaprant is safe and tolerable when added to standard antipsychotic treatment for schizophrenia. About 64 clinically stable outpatients will receive either aticaprant or a placebo. The main goals are to see if the study is feasible and to monitor side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
aticaprant (JNJ-67953964)
What this could lead to
If successful, this could point toward a new add-on treatment option for schizophrenia that is safe and tolerable.
What could go wrong
This is a very early Phase 1b trial with only 64 participants, focused on safety and feasibility, not on how well the drug works. Many drugs fail in early testing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CNS Network
RECRUITINGGarden Grove, California, 92845, United States
-
Community Clinical Research, Inc.
RECRUITINGAustin, Texas, 78754, United States
-
Evolution Research Group
RECRUITINGStaten Island, New York, 10314, United States
-
Neurobehavioral Research Inc
RECRUITINGCedarhurst, New York, 11516, United States
-
Pillar Clinical Research, LLC
RECRUITINGRichardson, Texas, 75080, United States
-
Synexus Clinical Research US Inc
RECRUITINGAtlanta, Georgia, 30328, United States
-
Uptown Research Institute
RECRUITINGChicago, Illinois, 60640, United States
-
Western Michigan University
RECRUITINGKalamazoo, Michigan, 49008, United States